Lung cancer
Conditions
Interventions
experimental group:DEB-BACE+Anlotinib+Adebelimumab
Sponsors
Ningbo Medical Center Li Huili Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Age>18 years old, gender unlimited,According to the Diagnosis and Treatment Guidelines for Primary Lung Cancer (2018 Edition), the pathological diagnosis of NSCLC was made by histological examination,TNM staging is III - IV,Failure of second-line treatment according to CSCO guidelines,ECOG PS score = 2 points,Expected survival time>3 months,Sign informed consent form
Exclusion criteria
Exclusion criteria: Individuals who have previously received interventional therapy (iodine particle implantation, ablation, BACE treatment), or have received PD-L1 inhibitor immunotherapy during the first or second line standard treatment period of the patient,Patients with other malignant tumors that have not been cured,White blood cells176.8) µ Mol/L, Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT)>twice the normal upper limit),Central squamous cell carcinoma with cavity features,Uncorrectable coagulation dysfunction or concomitant active massive hemoptysis,Patients with concurrent active infections who require antibiotic treatment,Uncontrollable hypertension, diabetes, cardiovascular disease with obvious symptoms,Contrast agent allergy,Women with concurrent pregnancy or lactation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective relief rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Progression free survival;Disease control rate;Duration of relief;safety; | — |
Countries
China
Contacts
Public ContactKaitai Liu
Ningbo Medical Center Li Huili Hospital
Outcome results
None listed